Pelthos Therapeutics Q3 2026 Results: Net Loss of $7.89M, Loss Narrows
Pelthos Therapeutics reported total revenue of $41.9 million for the nine months ended September 30, 2026, a significant increase from $7.4 million in the prior year. Despite the revenue growth, the company recorded a net loss of $56.4 million due to high selling, general, and administrative expenses and a $9.3 million loss from the change in fair value of convertible debt.
- Key figure
- Net loss $7.89M